Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1501 to 1550 of 1968 results for news

  1. SecurAcath for securing percutaneous catheters (HTG440)

    Evidence-based recommendations on SecurAcath for securing percutaneous catheters.

  2. Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)

    Evidence-based recommendations on secukinumab (Cosentyx) for active moderate to severe hidradenitis suppurativa (acne inversa) in adults.

  3. Nintedanib for treating progressive fibrosing interstitial lung diseases (TA747)

    Evidence-based recommendations on nintedanib for treating progressive fibrosing interstitial lung diseases in adults.

  4. Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer (HTG315)

    Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in people having breast cancer surgery.

  5. The Space GlucoseControl system for managing blood‑glucose in critically ill patients in intensive care (MIB17)

    NICE has developed a Medtech Innovation Briefing (MIB) on the Space GlucoseControl system for managing blood-glucose in critically ill patients in intensive care

  6. Child abuse and neglect (NG76)

    This guideline covers recognising and responding to abuse and neglect in children and young people aged under 18. It covers physical, sexual and emotional abuse, and neglect. The guideline aims to help anyone whose work brings them into contact with children and young people to spot signs of abuse and neglect and to know how to respond. It also supports practitioners who carry out assessments and provide early help and interventions to children, young people, parents and carers.

  7. Heart valve disease presenting in adults: investigation and management (NG208)

    This guideline covers investigation and management of heart valve disease presenting in adults. It aims to improve quality of life and survival for people with heart valve disease through timely diagnosis and appropriate intervention.

  8. Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer (TA741)

    Evidence-based recommendations on apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer in adults.

  9. Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over (TA1093)

    Evidence-based recommendations on idebenone (Raxone) for treating visual impairment in Leber’s hereditary optic neuropathy in people 12 years and over.

  10. Commercial access agreements

    The NICE commercial liaison team aim to reduce the workload for the NHS and frontline staff by making commercial agreements more straightforward.

  11. Spiral Flow peripheral vascular graft for treating peripheral arterial disease (MIB34)

    NICE has developed a medtech innovation briefing (MIB) on the Spiral Flow peripheral vascular graft for treating peripheral arterial disease

  12. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (HTG719)

    Evidence-based recommendations on tumour profiling tests (EndoPredict, ICH4+C, MammaPrint, Oncotype DX and Prosigna) to guide adjuvant chemotherapy decisions in early breast cancer.

  13. Digital platforms to support cardiac rehabilitation: early value assessment (HTG764)

    Early value assessment (EVA) on digital platforms to support cardiac rehabilitation.

  14. Digital technologies for the detection of melanoma (MIB311)

    NICE has developed a medtech innovation briefing (MIB) on digital technologies for the detection of melanoma .

  15. Record numbers accessing HIV prevention treatment

    Pre-exposure prophylaxis (PrEP) became routinely available through sexual health clinics in 2020, with NICE recommending the tablets for people at high risk of HIV in 2021.

  16. Prioritising our guidance topics

    Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.

  17. Violence and aggression: short-term management in mental health, health and community settings (NG10)

    This guideline covers the short-term management of violence and aggression in adults (aged 18 and over), young people (aged 13 to 17) and children (aged 12 and under). It is relevant for mental health, health and community settings. The guideline aims to safeguard both staff and people who use services by helping to prevent violent situations and providing guidance to manage them safely when they occur.

  18. Prioritisation board decisions 2024

    Our centralised approach to prioritising guidance topics ensures that we produce guidance that is relevant, timely, accessible, and has demonstrable impact.

  19. Artificial intelligence (AI)-derived software to help clinical decision making in stroke (HTG708)

    Evidence-based recommendations on artificial intelligence-derived software to help clinical decision making in stroke.

  20. The SpyGlass direct visualisation system for diagnostic and therapeutic procedures during endoscopy of the biliary system (MIB21)

    NICE has developed a Medtech Innovation Briefing (MIB) on the SpyGlass direct visualisation system for diagnostic and therapeutic procedures during endoscopy of

  21. First HIV prevention injection for people unable to have daily PrEP recommended

    A ground-breaking HIV-1 prevention injection has been recommended by NICE, marking a significant advance for a small group of adults and young people unable to have daily pre-exposure prophylaxis (PrEP) tablets.

  22. Lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care (HTG508)

    Evidence-based recommendations on lead-I electrocardiogram (ECG) devices (imPulse, Kardia Mobile, MyDiagnostick and Zenicor-ECG) for detecting symptomatic atrial fibrillation using single time point testing in primary care.

  23. Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over (TA1051)

    Evidence-based recommendations on efanesoctocog alfa (Altuvoct) for treating and preventing bleeding episodes in haemophilia A in people 2 years and over.

  24. Our prioritisation decisions

    NICE's decisions on how we prioritise topics, by year.

  25. Pancreatitis (NG104)

    This guideline covers managing acute and chronic pancreatitis in children, young people and adults. It aims to improve quality of life by ensuring that people have the right treatment and follow-up, and get timely information and support after diagnosis.

  26. Appraisal methodology for records 1999-2013

    Appraisal is the process of determining which records have continuing business or historical value from those which have no further value and should be disposed of appropriately.

  27. Depth of anaesthesia monitors – Bispectral Index (BIS), E-Entropy and Narcotrend-Compact M (HTG292)

    Evidence-based recommendations on 3 electroencephalography (EEG)-based depth of anaesthesia monitors for assessing a patient’s response to anaesthetic drugs during surgery. The monitors are Bispectral Index (BIS), E-Entrophy and Narcotrend-Compact M.

  28. Our chief executive, Dr Sam Roberts, welcomes the government's 10 Year Plan for healthcare

    The government's 10 Year Plan marks a pivotal moment for healthcare and strengthens NICE’s role.

  29. Video laryngoscopes to help intubation in people with difficult airways (MIB167)

    NICE has developed a medtech innovation briefing (MIB) on video laryngoscopy to help intubation in people with difficult airways .

  30. Tackling variation in rehab for people with neurological conditions

    NICE has recommended a standardised approach for rehabilitation, to address the variation of care experienced by millions of people with chronic neurological conditions.

  31. Evidence standards framework for digital health technologies (ECD7)

    This document describes an evidence standards framework (ESF) for digital health technologies (DHTs). It was developed by NICE between June 2018 and February 2019 in collaboration with NHS England, Public Health England and MedCity. The work was commissioned by NHS England

  32. Antimicrobials evaluation panel members

    Read the biographies for all members of the NICE antimicrobial evaluation committee.

  33. LARS for reconstructing damaged intra-articular cruciate knee ligaments (MIB30)

    NICE has developed a medtech innovation briefing (MIB) on LARS for reconstructing damaged intra-articular cruciate knee ligaments

  34. Should NICE's cost-effectiveness thresholds change?

    We explore the ongoing debate around NICE’s cost-effectiveness thresholds and what the future holds.

  35. Mechanical thrombectomy devices for acute ischaemic stroke (MIB153)

    NICE has developed a medtech innovation briefing (MIB) on mechanical thrombectomy devices for acute ischaemic stroke .

  36. Technology appraisal committee D members

    Find out more about NICE technology appraisals advisory committee D members

  37. Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (HTG360)

    Evidence-based recommendations on the My5-FU assay for measuring levels of 5-flurouracil (5-FU) in patients having chemotherapy, to help guide changes to the dose of 5-FU.

  38. Rapid tests for group A streptococcal infections in people with a sore throat (HTG531)

    Evidence-based recommendations on rapid tests for group A streptococcal infections in people aged 5 and over with a sore throat.

  39. Vutrisiran for treating transthyretin amyloidosis with cardiomyopathy (TA1115)

    Evidence-based recommendations on vutrisiran (Amvuttra) for wild-type or hereditary transthyretin amyloidosis with cardiomyopathy in adults.

  40. How NICE is helping to deliver the government's 10 Year Plan for healthcare

    Home News Podcasts How NICE is helping to deliver the government's 10 Year Plan for healthcare Podcasts 30 September 2025 Listen About...

  41. NICE joins international collaboration on HTA methods research

    We’ve partnered with the USA-based Institute for Clinical and Economic Review (ICER) and the Canadian Drug Agency (CDA-AMC) to establish the Health Economics Methods Advisory (HEMA), a new international initiative to research and evaluate health technology assessment (HTA) methods.

  42. VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions (HTG388)

    Evidence-based recommendations on the VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions.

  43. Paige Prostate for prostate cancer (MIB280)

    NICE has developed a medtech innovation briefing (MIB) on Paige Prostate for prostate cancer .

  44. Highly specialised technologies evaluation committee members

    Biographies for each member of the highly specialised technologies evaluation committee.

  45. Technology appraisal data: cancer appraisal recommendations

    Data on the cancer recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.

  46. Technology appraisal committee B members

    Find out more about the NICE technology appraisal advisory committee B members and their registered interests

  47. Same time decisions on licensing and value - what pharmaceutical companies need to know

    Learn how NICE and MHRA are launching an aligned pathway to accelerate patient access to medicines and provide a more efficient route for industry.

  48. A new model for evaluating and purchasing antimicrobials in the UK

    Overview of NICE and NHS England’s pioneering subscription-style purchasing model for antimicrobials: its pilot with ceftazidime-avibactam and cefiderocol in 2022, expansion in 2024, supporting health technology assessments, downloadable guidance and procurement tools.

  49. Technology appraisal committee A members

    Biographies and registered interests for members of the Technology Appraisal Committee A